Form 8-K
8-K — Microbot Medical Inc.
Accession: 0001493152-26-028824
Filed: 2026-06-16
Period: 2026-06-16
CIK: 0000883975
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-99.1 (ex99-1.htm)
GRAPHIC (ex99-1_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0000883975
0000883975
2026-06-16
2026-06-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 16, 2026
MICROBOT
MEDICAL INC.
(Exact
name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State
or other jurisdiction
of
incorporation)
(Commission
File
Number)
(IRS
Employer
Identification
No.)
175
Derby St., Bld. 27
Hingham,
MA 02043
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (781) 875-3605
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, $0.01 par value
MBOT
NASDAQ
Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
June 16, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has entered into a vendor
agreement with Lovell Government Services, which creates an opportunity to sell the Company’s LIBERTY® Endovascular
Robotic System at more than 2,000 U.S. government facilities.
The
press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information
in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be
deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number
Description
99.1
Press Release
104
Cover
Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
MICROBOT
MEDICAL INC.
By:
/s/
Harel Gadot
Name:
Harel
Gadot
Title:
Chief
Executive Officer, President and Chairman
Date:
June 16, 2026
EX-99.1
EX-99.1
Filename: ex99-1.htm · Sequence: 2
Exhibit
99.1
Microbot
Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
The
agreement with Lovell Government Services creates opportunities to sell the LIBERTY® System at more than
2,000 government facilities, including those administered by the U.S. Department of Veterans Affairs, the Department of
Defense, and the Indian Health Service.
HINGHAM,
Mass., June 16, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY®
Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare
systems, such as those administered by the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs,
the Military Health System (MHS), which is run by the U.S. Department of Defense, and the U.S. Indian Health Service (IHS). Lovell Government
Services will become the Company’s Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers
through federal contracting systems.
Lovell
Government Services has been a SDVOSB vendor since 2013 with a track record of introducing suppliers to the government market. Lovell
is a four-time Inc. 5000 honoree. Microbot Medical’s LIBERTY System will be added to Lovell’s Federal Supply Schedule
(FSS) contract, with activation expected during the third quarter of 2026. The LIBERTY System will also be accessible through additional
federal procurement platforms, including GSA Advantage, the Defense Logistics Agency’s Electronic Catalog (ECAT), and the Department
of Defense’s Distribution and Pricing Agreement (DAPA). Listing products with Lovell is expected to streamline the sales process
while helping government agencies meet their SDVOSB procurement goals. Lovell serves thousands of government care sites nationwide, including
170 medical centers and numerous outpatient clinics, averaging over 200 peripheral endovascular cases annually, per site.
“We
are proud to partner with Microbot Medical to help expand access to innovative healthcare technologies for our nation’s veterans,
active-duty service members, and Native American communities,” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government
Services. “The LIBERTY® Endovascular Robotic System represents a significant advancement in minimally invasive vascular
care, and we look forward to supporting its availability across federal healthcare systems. Our mission is to connect government providers
with best-in-class solutions that improve patient outcomes while simplifying the procurement process, and this partnership reflects that
commitment.”
“As
someone who has represented the U.S. in two Olympics, it is an honor to join
with Lovell to ensure those who have served in the military along with their physicians have access
to advanced medical technologies that address their needs,” commented Christina Bailey, Vice President, U.S. Sales. “Building
on our continued commercial momentum, we believe this partnership will expand awareness and adoption of our technology across Lovell’s
extensive network. Contracted access is a key component of our commercial strategy, providing customers with a streamlined procurement
pathway and confidence in product availability. As interest in our technology continues to grow, we believe now is the right time to
start this relationship and its potential for broader adoption.”
About
Microbot Medical
Microbot
Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced
robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic
solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation,
Microbot is driving the future of endovascular care.
Learn
more at www.microbotmedical.com and connect on LinkedIn and X.
Safe
Harbor
Statements
to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development,
commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including,
but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,”
“intends,” “may,” “might,” “possible,” “potential,” “predicts,”
“projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular
Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory
pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes
in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual
property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors”
in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s
web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements,
except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
GRAPHIC
GRAPHIC
Filename: ex99-1_001.jpg · Sequence: 3
Binary file (17141 bytes)
Download ex99-1_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 19
v3.26.1
Cover
Jun. 16, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Jun. 16, 2026
Entity File Number
000-19871
Entity Registrant Name
MICROBOT
MEDICAL INC.
Entity Central Index Key
0000883975
Entity Tax Identification Number
94-3078125
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
175
Derby St.
Entity Address, Address Line Two
Bld. 27
Entity Address, City or Town
Hingham
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
02043
City Area Code
(781)
Local Phone Number
875-3605
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, $0.01 par value
Trading Symbol
MBOT
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration